Myeloma Community and Education


Register Now for the November 2nd IMF Patient and Family Webinar Register now for the upcoming IMF Patient and Family Webinar on Thursday, November 2, at 2:30 p.m. PT \| 3:30 p.m. MT \|4:30 p.m. CT \| 5:30 p.m. ET. IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will present Myeloma 101. IMF Nurse Leadership Board Member Mary Steinbach, DNP, DPRN, will cover managing side effects and complications of myeloma care. Dr. Rafat Abonour will focus on frontline treatment options. Finally, Dr. Ajai Chari will shed light on relapse and new immune therapies. At the end of each presentation, participants will have time to ask questions.


Register Now for the November 4th M-Power Community Workshop in Detroit At this M-Power Community Workshop, myeloma experts will discuss health empowerment and multiple myeloma awareness in the African American community. Check-in begins at 9:30 a.m. EST at Tabernacle Missionary Baptist Church (2080 W Grand Blvd) in Detroit. The workshop will take place from 10:00 a.m. to 12:30 p.m. EST, with refreshments provided.


European Medicines Agency Recommends Conditional Marketing Authorization of ELREXFIO™ (elranatamab) As of October 13, 2023, the European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) has recommended conditional marketing authorization for ELREXFIO™ (elranatamab) as a standalone treatment for adult patients with relapsed and refractory multiple myeloma. These patients must have undergone at least three prior therapies and experience worsened cancer since their last treatment.


Help Us Help You: Take This Survey on the Myeloma Minute Thank you so much for subscribing to the Myeloma Minute. If you have a moment, please complete our survey so we can improve this weekly newsletter. Thanks for your input!


Watch the Replay: M-Power Tampa 2023 Workshop on Health Equity and Myeloma Awareness Explore M-Power Tampa 2023, a workshop promoting Health Equity, which focused on raising awareness of multiple myeloma in the African American community. The M-Power Project strives to enhance outcomes for African American myeloma patients. The workshop featured IMF Chief Medical Officer Dr. Joseph Mikhael discussing myeloma, racial disparities, and the importance of early diagnosis. Drs. Brandon Blue and Kenneth Shain from the Moffitt Cancer Center emphasized the significance of addressing disparities in cancer care. IMF Nurse Leadership Board member Beth Finley Oliver, MSN, ARNP, AGNP-BC highlighted the importance of communication in myeloma care. Tune in also for an inspiring interview with myeloma patient and care partner team Gary and Nadia Lambert.


Donate Your Vehicle This Fall We’re participating in Cartober—a national campaign that raises awareness around this powerful means of giving. You, too, can participate by donating your vehicle to the IMF! The process is easy and free, and we’ll use the proceeds to fund our research, education, and support programs for the myeloma community. Bonus: We will provide you with the proper tax-deduction paperwork.


Medicare Open Enrollment Period Now Active Medicare's Open Enrollment Period is October 15 - December 7. This timeframe is your chance to explore Medicare Plans and see what works for you. Plans can change from year to year, and your health needs may change, too. The International Myeloma Foundation and our InfoLine team do not have recommendations about Medicare. We do, however, encourage you to explore Medicare.gov, or contact your local State Health Insurance Assistance Program (SHIP) to get the phone number for Medicare assistance for your state.


Treatment for Patients Not Going to Transplant Made Simple In this “Myeloma Made Simple” video, IMF Chief Medical Officer Dr. Joseph Mikhael discusses effective therapies for multiple myeloma patients who are ineligible for autologous stem cell transplant. Learn about novel combinations and regimens, including Velcade, Revlimid, and dexamethasone (VRd); and Darzalex, Revlimid, and dex (DRd). These three-drug regimens provide improved outcomes and fewer side effects.

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

Phase II Relapsed or Refractory Venetoclax Trial (Fully Accrued)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Ongoing & Upcoming Events

Donate Now
Jack's Cure Myeloma Grant

Donate Now
Fundraising for a Cure

Webinar Replays

Watch the Replay
IMF Patient and Family Seminar

Watch the Replay
IMF Virtual Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

AbbVie, Bristol Myers Squibb, GSK, Janssen Oncology, Karyopharm Therapeutics,
Pfizer, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

We also thank individuals like you for your continued support!

Join the conversation at The International Myeloma Foundation

Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma

www.myeloma.org

This email was sent to by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Manage Subscriptions • Privacy Policy

View as web page